Prebiotic Inulin Constipation Randomized Trial: What the Evidence Says

Quick Answer

Prebiotic Inulin Constipation Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 narrative review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• A clinical investigation found that 37.1% of individuals with IBS had depression and 31.4% had anxiety. [Akçalı Çağlar (2025); evidence level 2]
• It is found and obtained from plant sources such as chicory, yam, garlic, leek and onion. [Akçalı Çağlar (2025); evidence level 2]
• This, in turn, can lead to a more diverse and resilient gut microbiota, which is associated with positive health outcomes. [Monteiro Cinara Regina A. V. (2026); evidence level 3]
• Current literature often lacks an integrative analysis that bridges mechanistic insights rooted in prebiotic structure and function with heterogeneous clinical evidence derived from human trials. [Monteiro Cinara Regina A. V. (2026); evidence level 3]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For prebiotic inulin constipation randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Akçalı Çağlar (2025). A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation predominant IBS. DOI: 10.1038/s41598-025-16321-w. PMCID: PMC12488941. PMID: 41034384. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12488941/
• Monteiro Cinara Regina A. V. (2026). Prebiotics and Gut Health: Mechanisms, Clinical Evidence, and Future Directions. DOI: 10.3390/nu18030372. PMCID: PMC12899272. PMID: 41683196. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12899272/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.